What factors affect the test results of myocardial enzyme profile clinical diagnostic reagent assay kit

Myocardial enzyme spectrum detection is an important means of evaluating myocardial injury. Its detection indicators mainly include creatine kinase (CK) and its isoenzyme CK-MB, troponin (Troponin I and Troponin T), lactate dehydrogenase (LDH), aspartate aminotransferase (AST) and other myocardial injury markers, such as heart-type fatty acid binding protein H-FABP. These biomarkers will show different degrees of changes when myocardial injury occurs, providing important diagnostic basis for clinical practice.

Individual differences in patients have a significant impact on the test results. Physiological factors such as gender, age and race may lead to differences in test results. For example, men usually have higher CK activity than women because of their larger muscle mass; newborns may experience skeletal muscle damage and temporary hypoxia at birth, so CK levels are often elevated; and the CK level of the black population is about 1.5 times that of the white population. In addition, the patient's disease status is also a key factor affecting the test results. Diseases such as myocardial infarction, myocarditis, polymyositis, rhabdomyolysis and progressive muscular dystrophy can lead to a significant increase in myocardial enzyme indicators. In contrast, conditions such as hyperthyroidism, long-term bed rest and hormone therapy may reduce CK levels. Exercise status should not be ignored. CK levels will increase significantly after strenuous exercise, and the longer the intensity and duration of exercise, the more obvious the increase in CK.

The collection, transportation, storage and processing procedures of samples are crucial to the accuracy of the test results. The appearance time and peak time of different myocardial injury markers in the blood are different, so it is particularly important to grasp the time of sample collection. For example, troponin (Myo) is the only marker that can be detected early within 3 hours after myocardial infarction, while cTnI appears later, usually after 3 hours, which may affect the effect of early diagnosis. During the transportation of samples, the appropriate temperature should be ensured and violent shaking should be avoided to prevent sample deterioration. During storage, samples need to be stored at a specified temperature. For example, some samples need to be stored in an environment of 2 to 8°C, and can be stored for three weeks below -18°C, but repeated freezing and thawing should be avoided to avoid affecting the activity of the enzyme. During sample processing, the operating procedures must be strictly followed to prevent sample contamination or loss of enzyme activity.

The selection of detection methods and reagents will also affect the reliability of the test results. There are differences in the sensitivity and specificity of different detection methods. For example, the enzyme coupling method can continuously monitor the absorbance changes at a wavelength of 340nm by monitoring the process of NADP reduction to generate NADPH, thereby calculating the active concentration of CK. This method has high accuracy. At the same time, the quality, stability and calibration status of the reagents will also affect the results. Expired or improperly stored reagents, as well as inaccurate calibration, may lead to deviations in the test results.

The impact of drugs on the test results cannot be ignored either. Some commonly used antiviral drugs, interferons, etc. may interfere with the test results of myocardial enzyme spectrum. Although the impact of all drugs has not yet been fully studied, in the clinical testing process, the patient's medication situation should be comprehensively considered, and corresponding adjustments and judgments should be made when necessary to ensure the accuracy and reliability of the test results. By comprehensively considering the above factors, the clinical application value of myocardial enzyme spectrum detection can be effectively improved, providing a solid foundation for the early diagnosis and treatment of cardiovascular diseases.